Evidence map›Paper›PMID 25867583›Full record

ArticleStem cells and development2015

Clonogenically Culturing and Expanding CD34+ Liver Cancer Stem Cells in Vitro.

Su Cheol Park, Changjun Zeng, Benjamin Tschudy-Seney, Ngoc Tue Nguyen, Jong Ryeol Eun, Yanling Zhang, Rajendra Ramsamooj, Yanghong Zhang, Min Zhao, Neil D Theise and 3 more

Open access · greenAbstract read
In one paragraph

Article in Stem cells and development, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Establishment of a prognostic model based on mJournal of cancer research and clinical oncology · 2023
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Su Cheol Park1 Department of Internal Medicine, University of California Davis Medical Center , Sacramento, California.
Changjun Zeng1 Department of Internal Medicine, University of California Davis Medical Center , Sacramento, California.
Benjamin Tschudy-Seney1 Department of Internal Medicine, University of California Davis Medical Center , Sacramento, California.
Ngoc Tue Nguyen1 Department of Internal Medicine, University of California Davis Medical Center , Sacramento, California.
Jong Ryeol Eun1 Department of Internal Medicine, University of California Davis Medical Center , Sacramento, California.
Yanling Zhang1 Department of Internal Medicine, University of California Davis Medical Center , Sacramento, California.
Rajendra Ramsamooj7 Department of Pathology and Laboratory Medicine, University of California Davis Medical Center , Sacramento, California.
Yanghong Zhang7 Department of Pathology and Laboratory Medicine, University of California Davis Medical Center , Sacramento, California.
Min Zhao8 Department of Dermatology, University of California Davis Medical Center , Sacramento, California.
Neil D Theise9 Department of Pathology and of Medicine, Beth Israel Medical Center , Albert Einstein College of Medicine, New York, New York.
Huaijun Zhou10 Department of Animal Science, University of California at Davis , Davis, California.
Mark A Zern1 Department of Internal Medicine, University of California Davis Medical Center , Sacramento, California.
Yuyou Duan1 Department of Internal Medicine, University of California Davis Medical Center , Sacramento, California.
University of California Davis Medical Center · USSichuan Agricultural University · CNSouthern Medical University · CNUniversity of California, Davis · USYeungnam University College

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Differentiating Human ESC Towards HepatocytesR01DK075415 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ZERN, MARK ALLEN · 2007 to 2010
$1.3M
NCI NIH HHS P30 CA093373NIDDK NIH HHS DK075415
6 · The paper itself

Abstract

A large number of cancer stem cells (CSCs) have been isolated and identified; however, none has been cultured in an unlimited manner in vitro without losing tumorigenicity and multipotency. In this study, we successfully clonogenically cultured a newly identified CD34+ liver CSC (LCSC) on feeder cells up to 22 passages (to date) without losing CSC property. Cloned CD34+ LCSC formed a round packed morphology and it could also be cryopreserved and recultured. Stem cell markers, CD34, CD117, and SOX2; normal liver stem cell markers, alpha fetoprotein, CK19, CK18, and OV6; putative CSC markers, CD44, CD133, EpCAM, and CD90; as well as CD31 were expressed in cloned CD34+ LCSC. SOX2 was the major factor in maintaining this LCSC before colonization, and interestingly, OCT4, SOX2, NAONG, Klf4, c-Myc, and Lin28 were upregulated in association with symmetric self-renewal for colony growth of CD34+ LCSC on feeder cells. Gene expression patterns of in vitro differentiation were consistent with our in vivo finding; furthermore, the tumorigenicity of cloned CD34+ LCSC was not different from uncloned CD34+ LCSC sorted from parental PLC. These results show that our cloned CD34+ LCSC maintained CSC property, including self-renewal, bipotency, and tumorigenicity after long-term culture, demonstrating that this LCSC can be cultured in an unlimited manner in vitro. Thus, establishing pure population of CSCs isolated from the patients will provide an opportunity to explore the mechanisms of tumorigenesis and cancer development, and to identify unique biomarkers presenting potential indicators of drug efficacy against CSCs for establishment of a novel strategy for cancer therapy.

Indexed as

Cell ProliferationAnimalsAntigens, CD34Biomarkers, TumorCarcinoma, HepatocellularCell Line, TumorHumansKruppel-Like Factor 4Liver NeoplasmsMiceMice, Inbred NODMice, SCIDNeoplastic Stem CellsAntigens, CD34Biomarkers, TumorKLF4 protein, humanKlf4 protein, mouseKruppel-Like Factor 4

Identifiers

PMID25867583
PMCPMC4499771
OpenAlexW2314335481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.